Altimmune (ALT) Q2 FY26 earnings call

Altimmune is rapidly advancing its pemvidutide liver franchise, initiating the global PERFORMA Phase 3 trial for MASH and reporting robust Phase 2 data for Alcohol Use Disorder (AUD). The company is focused on leveraging pemvidutide's differentiated dual mechanism to address serious liver diseases, with a strong cash position supporting its MASH program through 2029. Management plans to pursue non-dilutive funding for the AUD Phase 3 trial.